RESELIGO

This brand name is authorized in Estonia, Croatia, Lithuania, Malta, Poland, Romania

Active ingredients

The drug RESELIGO contains one active pharmaceutical ingredient (API):

1 Goserelin UNII 6YUU2PV0U8 - GOSERELIN ACETATE

Goserelin is a synthetic analogue of naturally occurring LHRH. On chronic administration goserelin results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females. Read about Goserelin

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L02AE03	Goserelin	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02A Hormones and related agents → L02AE Gonadotropin releasing hormone analogues
Discover more medicines within L02AE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1648403, 1648414, 1648425, 1648436
Country: HR	Agencija za lijekove i medicinske proizvode	Identifier(s): HR-H-731754823, HR-H-863040656
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1073399, 1078715
Country: MT	Medicines Authority	Identifier(s): AA565/93601, AA565/93602
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100356580, 100356596
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68571001, W68571002, W68572001, W68572002